Nephros (NEPH) Projected to Post Earnings on Thursday

Nephros (NASDAQ:NEPH) is projected to post its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect Nephros to post earnings of $0.01 per share and revenue of $4.4510 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Nephros Price Performance

NEPH stock opened at $3.87 on Friday. Nephros has a 12 month low of $1.49 and a 12 month high of $6.42. The firm’s 50-day moving average is $4.33 and its 200 day moving average is $4.65. The company has a market capitalization of $41.14 million, a PE ratio of 29.77 and a beta of 1.42.

Hedge Funds Weigh In On Nephros

Several institutional investors have recently made changes to their positions in NEPH. Topline Capital Management LLC raised its holdings in shares of Nephros by 13.1% in the second quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock valued at $1,953,000 after acquiring an additional 55,360 shares in the last quarter. Renaissance Technologies LLC increased its position in Nephros by 25.8% during the 4th quarter. Renaissance Technologies LLC now owns 103,772 shares of the company’s stock valued at $506,000 after purchasing an additional 21,272 shares during the period. Geode Capital Management LLC raised its holdings in shares of Nephros by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock valued at $381,000 after purchasing an additional 2,898 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Nephros by 7.2% in the 4th quarter. HighTower Advisors LLC now owns 59,710 shares of the company’s stock valued at $291,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC lifted its position in shares of Nephros by 57.1% in the 4th quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock worth $190,000 after purchasing an additional 14,162 shares during the period. Hedge funds and other institutional investors own 41.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Nephros in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.